SEC Contract Filing

Filing Date: 2024-03-18

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102-elicioxpipepr.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit102-elicioxpipepr</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit102-elicioxpipepr001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit102-elicioxpipepr001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> 4125-1938-3119.3 THE OFFER AND SALE OF THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN EACH CASE IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES; PROVIDED THAT IN CONNECTION WITH ANY FORECLOSURE OR TRANSFER OF THE SECURITIES, THE TRANSFEROR SHALL COMPLY WITH THE PROVISIONS HEREIN AND IN THE SUBSCRIPTION AGREEMENT, AND UPON FORECLOSURE OR TRANSFER OF THE SECURITIES, SUCH FORECLOSING PERSON OR TRANSFEREE SHALL COMPLY WITH ALL PROVISIONS CONTAINED HEREIN AND IN THE SUBSCRIPTION AGREEMENT. ELICIO THERAPEUTICS, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [&#8226;] (subject to adjustment) Warrant No. [&#8226;] Original Issue Date: [&#8226;] Elicio Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, GKCC, LLC (the &#8220;Holder&#8221;), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [&#8226;] shares of common stock, $0.01 par value per share (the &#8220;Common Stock&#8221;), of the Company (each such share, a &#8220;Warrant Share&#8221; and all such shares, the &#8220;Warrant Shares&#8221;) at an exercise price per share equal to $0.01 per share (as adjusted from time to time as provided in Section 9 herein, the &#8220;Exercise Price&#8221;), upon surrender of this Pre-Funded Warrant to Purchase Common Stock (the &#8220;Warrant&#8221; (which, for the avoidance of doubt, shall include any New Warrant (as defined below))) at any time and from time to time on or after the date hereof (the &#8220;Original Issue Date&#8221;), subject to the following terms and conditions: This Warrant is issued pursuant to that certain Subscription Agreement, dated March 18, 2024, by and among the Company and the Holder (the &#8220;Subscription Agreement&#8221;). All such Warrants are referred to herein, collectively, as the &#8220;Warrants.&#8221; </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit102-elicioxpipepr002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit102-elicioxpipepr002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> 2 4125-1938-3119.3 1. Definitions. In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Subscription Agreement. For purposes of this Warrant, the following terms shall have the following meanings: (a) &#8220;Closing Sale Price&#8221; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets (such time, the &#8220;Close of Trading&#8221;). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined in good faith by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors shall use its good faith judgment to determine the fair market value. The Board of Directors&#8217; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. 2. Warrant Register. The Company shall register ownership of this Warrant, upon records to be maintained by or on behalf of the Company for that purpose (the &#8220;Warrant Register&#8221;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice